Cover Image
市場調查報告書

眼科用藥的全球市場的未來預測

Ophthalmic Drugs Global Market Forecast 2016-2021

出版商 Labrinth Analytics LTD 商品編碼 359776
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
眼科用藥的全球市場的未來預測 Ophthalmic Drugs Global Market Forecast 2016-2021
出版日期: 2016年04月04日 內容資訊: 英文
簡介

本報告提供全球眼科用藥市場相關分析,關於整體市場結構和競爭狀態,市場促進、阻礙因素,各地區、各症狀的市場趨勢預測,主要企業簡介、市場佔有率、開發中產品等調查評估。

第1章 過去的市場資料 (過去4年份)

第2章 主要企業

  • Novartis
  • Merck, Inc
  • Pfizer, Inc.
  • Bayer AG
  • 參天製藥

第3章 眼科用藥市場質性分析 (今後11年份)

  • Novartis (開發中產品)
  • Bayer (開發中產品)
  • 參天製藥 (開發中產品)
  • Pfizer, Inc. (開發中產品)
  • Roche Holding, Inc. (開發中產品)
  • 價值鏈分析
  • SWOT分析
  • 大環境分析
  • 市場促進、阻礙因素

第4章 主要國家的眼科用藥市場 (今後11年份)

  • 全球眼科用藥市場:各地區的明細
  • 全球眼科用藥市場:各地區的未來預測 (今後11年份)
  • 美國市場 (今後11年份)
  • 加拿大市場 (今後11年份)
  • 德國市場 (今後11年份)
  • 義大利市場 (今後11年份)
  • 英國市場 (今後11年份)
  • 法國市場 (今後11年份)
  • 西班牙市場 (今後11年份)
  • 其他的歐洲各國的市場 (今後11年份)
  • 日本市場 (今後11年份)
  • 中國市場 (今後11年份)
  • 印度市場 (今後11年份)
  • 其他的亞太地區各國的市場 (今後11年份)
  • 巴西市場 (今後11年份)
  • 墨西哥市場 (今後11年份)
  • 其他的南美各國的市場 (今後11年份)
  • 其他的國家 (RoW)的市場 (今後11年份)

第5章 各症狀的市場區隔 (今後7年份)

  • 老年性黃斑部病變 (AMD) 市場:目前治療數量
  • 老年性黃斑部病變市場:收益額預測 (今後12年份)
  • 青光眼市場預測 (今後6年份)
  • 視網膜障礙市場預測 (今後6年份)
  • 過敏市場預測 (今後6年份)
  • 乾眼症市場預測 (今後6年份)

第6章 表格一覽

第7章 圖的一覽

第8章 分析對象企業、團體的一覽

目錄

The global ophthalmic market was valued at $ XXXX m in 2015 and is expected to reach $ XXXX m, at a CAGR of XXXX % during 2015-2021. The US was the largest market for ophthalmic drugs, accounted for XXXX % of the global market. Glaucoma was the largest segment in the global ophthalmic market and accounted for XXXX % share in 2015. Rise in ageing population, innovative products in the pipeline and growing healthcare infrastructure in the developing nations will boost market growth in the future.

image1

image2

image3

image4

image5

Table of Contents

1. Historical Data

  • 1.1 Ophthalmic Drugs Market 2012
  • 1.2 Ophthalmic Drugs Market 2013
  • 1.3 Ophthalmic Drugs Market 2014
  • 1.4 Ophthalmic Drugs Market 2015

2. Leading Companies in the World Ophthalmic Market

  • 2.1 Novartis
  • 2.2 Merck, Inc
  • 2.3 Pfizer, Inc.
  • 2.4 Bayer AG
  • 2.5 Santen Pharmaceuticals Company Ltd.

3. Qualitative Analysis of the Ophthalmic drugs Market 2016-2026

  • 3.1 Novartis (Pipeline)
  • 3.2 Bayer (Pipeline)
  • 3.3 Santen Pharmaceutical Company Ltd. (Pipeline)
  • 3.4 Pfizer, Inc. (Pipeline)
  • 3.5 Roche Holding, Inc. (Pipeline)
  • 3.6 Value Chain Analysis
  • 3.7 SWOT Analysis of the Ophthalmic Drugs Market 2016 - 2021
  • 3.8 Pestle Analysis of the Ophthalmic Drugs Market 2016 - 2021
  • 3.9 Market Drivers and Barriers

4. Leading National Markets for the Ophthalmic Drugs Market 2016-2021

  • 4.1 Regional Breakdown of the World Ophthalmic Drugs Market 2014-2015
  • 4.2 World Ophthalmic Drugs Market: Regional Forecast 2016-2021
  • 4.3 The US Ophthalmic Drugs Market Forecast 2016-2021
  • 4.4 The Canada Ophthalmic Drugs Market Forecast 2016-2021
  • 4.5 The Germany Ophthalmic Drugs Market Forecast 2016-2021
  • 4.6 The Italy Ophthalmic Drugs Market Forecast 2016-2021
  • 4.7 The U.K. Ophthalmic Drugs Market Forecast 2016-2021
  • 4.8 The France Ophthalmic Drugs Market Forecast 2016-2021
  • 4.9 The Spain Ophthalmic Drugs Market Forecast 2016-2021
  • 4.10 The rest of Europe Ophthalmic Drugs Market Forecast 2016-2021
  • 4.11 The Japan Ophthalmic Drugs Market Forecast 2016-2021
  • 4.12 The China Ophthalmic Drugs Market Forecast 2016-2021
  • 4.13 The India Ophthalmic Drugs Market Forecast 2016-2021
  • 4.14 The rest of Asia Ophthalmic Drugs Market Forecast 2016-2021
  • 4.15 The Brazil Ophthalmic Drugs Market Forecast 2016-2021
  • 4.16 The Mexico Ophthalmic Drugs Market Forecast 2016-2021
  • 4.17 The rest of Latin America Ophthalmic Drugs Market Forecast 2016-2021
  • 4.18 The rest of the World Ophthalmic Drugs Market Forecast 2016-2021

5. Ophthalmic Drugs Treatment by Condition, 2015 - 2021

  • 3.1 The Global Market for AMD Drugs Treatments in 2014
  • 3.2 The World AMD Drugs Market: Revenue Forecasts 2015-2026
  • 3.3 Glaucoma Market Forecast 2016 - 2021
  • 3.4 Retinal Disorder Market Forecast 2016 - 2021
  • 3.5 Allergy Market Forecast 2016 - 2021
  • 3.4 Dry Eye Disorder Market Forecast 2016 - 2021

6. List of Tables

  • Novartis: Historical Sales ($m, AGR%), 2011-2014
  • Merck: Historical Sales ($m, AGR%), 2011-2014
  • Pfizer: Historical Sales ($m, AGR%), 2011-2014
  • Bayer: Historical Sales ($m, AGR%), 2011-2014
  • Santen: Historical Sales ($m, AGR%), 2011-2014
  • Table 1 Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Country, 2016-2021 (Redacted Data)
  • Table 2 ICD 10 Classification of Visual Impairment, 2010
  • Table 3 Drug Treatments For Glaucoma, 2016
  • Table 4 Drug Treatments For Age-Related Macular Degeneration, 2016
  • Table 5 Drug Treatments For Ocular Allergy, 2016
  • Table 6 Drug Treatments For Ocular Inflammatory Disease, 2016
  • Table 7 Drug Treatments For Eye Infections, 2016
  • Table 8 Clinical Trial Phases, 2016
  • Table 9 The Global Ophthalmic Drugs Market: Revenue ($m) and Market Shares (%) by Sector, 2015
  • Table 10 The Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2015-2021
  • Table 11 Top Drugs In The Retinal Disorder Drugs Market: Revenue ($m) and Market Shares (%), 2016
  • Table 12 Retinal Disorder Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2015-2021
  • Table 13 Lucentis: Novartis/ Roche Sales Forecast ($m, AGR%, CAGR%), 2011-2014
  • Table 14 Eylea: Regeneron/ Bayer/ Santen Sales Forecast ($m, AGR%, CAGR%), 2011-2014
  • Table 15 Avastin: Ophthalmic Sales Forecast ($m, AGR%, CAGR%), 2011-2014
  • Table 16 Visudyne: Sales Forecast ($m, AGR%, CAGR%), 2014-2014
  • Table 17 Jetrea: ThromboGenics/ Novartis Sales Forecast ($m, AGR%, CAGR%), 2011-2014
  • Table 18 Other Retinal Disorder Drugs: Sales Forecast ($m, AGR%, CAGR%), 2014-2021 Table 19 Leading Drugs In The Allergic, Inflammatory and Infective Drugs Market: Revenue ($m) and Market Shares (%), 2015
  • Table 20 Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2014-2021
  • Table 21 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2014, 2019,
  • Table 22 Pataday: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%, CAGR%), 2014-2021
  • Table 23 Patanol: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%, CAGR%), 2014-2021
  • Table 24 Vigamox: Novartis Sales Forecast ($m, AGR%, CAGR%), 2014-2021
  • Table 25 TobraDex: Sales Forecast ($m, AGR%, CAGR%), 2014-2021
  • Table 26 Bromday: Sales Forecast ($m, AGR%, CAGR%), 2014-2021
  • Table 27 Cravit: Sales Forecast ($m, AGR%, CAGR%), 2014-2021
  • Table 28 Acular: Sales Forecast ($m, AGR%, CAGR%), 2014-2021
  • Table 29 AzaSite: Akorn Sales Forecast ($m, AGR%, CAGR%), 2014-2021
  • Table 20 Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast ($m, AGR%, CAGR%), 2014-2021
  • Table 21 Leading Glaucoma Drugs: Revenues ($m) and Market Shares (%), 2014
  • Table 22 Glaucoma Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2014-2021
  • Table 22 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2014, 2019,
  • Table 23 Lumigan and Ganfort: Sales Forecast ($m, AGR%, CAGR%), 2014-2021
  • Table 24 Xalatan/Xalacom: Sales Forecast ($m, AGR%, CAGR%), 2014-2021
  • Table 27 Travatan/Travatan Z and DuoTrav: Sales Forecast ($m, AGR%, CAGR%), 2014-2021
  • Table 28 Alphagan/Alphagan P and Combigan: Sales Forecast ($m, AGR%, CAGR%), 2014-2021
  • Table 29 Trusopt: Merck/Santen Sales Forecast ($m, AGR%, CAGR%), 2014-2021
  • Table 30 Cosopt/Cosopt PF: Akorn/Merck/Santen Sales Forecast ($m, AGR%, CAGR%), 2014-2021
  • Table 31 Azopt: Novartis Sales Forecast ($m, AGR%, CAGR%), 2014-2021
  • Table 32 Tapros: Santen Sales Forecast ($m, AGR%, CAGR%), 2014-2021
  • Table 33 Zioptan: Akorn Sales Forecast ($m, AGR%, CAGR%), 2014-2021
  • Table 34 Other Glaucoma Drugs: Sales Forecast ($m, AGR%, CAGR%), 2014-2021
  • Table 35 Leading Dry Eye Drugs: Revenues ($m) and Market Shares (%), 2014
  • Table 36 Dry Eye Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2014-2021
  • Table 37 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2014, 2019
  • Table 38 Refresh Brand: Allergan (Actavis) Sales Forecast ($m, AGR%, CAGR%), 2014-2021 Table 39 Hyalein: Santen Sales Forecast ($m, AGR%, CAGR%), 2014-2021
  • Table 40 Diquas: Santen Sales Forecast ($m, AGR%, CAGR%), 2014-2021
  • Table 41 Other Dry Eye Drugs: Sales Forecast ($m, AGR%), 2014-2021
  • Table 42 Hetlioz: Vanda Pharma Sales Forecast ($m, AGR%, CAGR%), 2014-2021
  • Table 43 North America Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021 Table 44 The U.S. Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 45 Canada Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 45 Europe Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 46 Germany Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 47 France Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 48 U.K. Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 49 Italy Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 49 Spain Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 50 Rest of Europe Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021 Table 51 Asia Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 52 Japan Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 53 China Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 54 India Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 55 Rest of Asia Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021 Table 56 Latin America Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021 Table 57 Brazil Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 58 Mexico Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 59 Rest of Latin America Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 60 Rest of the World Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 61 Market Share Analysis by Country 2015 (%)Table 9.15 Valeant: Company Overview, 2015
  • Table 62 Valeant: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2021 Table 63 Pfizer: Company Overview, 2015
  • Table 64 Pfizer: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2021
  • Table 65 Bayer: Company Overview, 2015
  • Table 66 Bayer: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2021
  • Table 67 Senju: Company Overview, 2015
  • Table 68 Senju: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2021
  • Table 69 Retinal Disorders Drugs Pipeline: Phase 3 Drugs, 2015
  • Table 70 Retinal Disorders Drugs Pipeline: Phase 2 Drugs, 2015
  • Table 72 Retinal Disorders Drugs Pipeline: Phase 1 and Pre-clinical Drugs, 2015
  • Table 73 Allergic, Inflammatory and Infective Drugs Pipeline: Phase 3 Drugs, 2015
  • Table 74 Allergic, Inflammatory and Infective Drugs Pipeline: Phase 2 Drugs, 2015
  • Table 75 Allergic, Inflammatory and Infective Drugs Pipeline: Phase 1 and Pre-clinical Drugs, 2015
  • Table 76 Glaucoma Drugs Pipeline: Phase 2&3 Drugs, 2015
  • Table 77 Glaucoma Drugs Pipeline: Phase 1 and Pre-clinical Drugs, 2015
  • Table 78 Dry Eye Drugs Pipeline: Phase 3 Drugs, 2015
  • Table 79 Dry Eye Drugs Pipeline: Phase 2 Drugs, 2015
  • Table 80 Other Pipeline Products for Ophthalmic Conditions, 2015
  • Table 81 SWOT Analysis of the Global Ophthalmic Drugs Market, 2015-2021
  • Table 82 World 65+ Population Forecast: Size (m), AGR (%), CAGR (%), 2014-2021
  • Table 83 Global Prevalence Forecast for Ophthalmic Diseases from 2014
  • Table 84 Global Ophthalmic Drugs: Market Forecast ($m, CAGR%), 2014, 2018, 2021, 2021 Table 85 The Global Ophthalmic Drugs Market: Market Forecast ($m) by Region, 2014, 2018, 2021

7 Lists of Figures

  • Figure 1 Global Ophthalmic Drugs Market Segmentation Overview, 2015
  • Figure 2 Novartis: Historical Sales ($m, AGR%), 2011-2014
  • Figure 3 Merck: Historical Sales ($m, AGR%), 2011-2014
  • Figure 4 Pfizer: Historical Sales ($m, AGR%), 2011-2014
  • Figure 5 Bayer: Historical Sales ($m, AGR%), 2011-2014
  • Figure 6 Santen: Historical Sales ($m, AGR%), 2011-2014
  • Figure 7 North America Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 8 The U.S. Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 9 Canada Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 10 Europe Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 11 Germany Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 12 France Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 13 U.K. Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 14 Italy Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 15 Spain Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 16 Rest of Europe Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 17 Asia Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 18 Japan Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 19 China Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 20 India Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 21 Rest of Asia Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 22 Latin America Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 23 Brazil Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 24 Mexico Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 25 Rest of Latin America Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 26 Rest of the World Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 27 Market Share Analysis by Country, 2015 (%)
  • Figure 28 Global Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 29 Glaucoma Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 30 Retinal Disease Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 31 Inflammation Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 32 Dry Eye Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 33 Market Share Analysis by Disease Condition, 2015 (%)

8 Companies and Other Organizations Mentioned

  • EMA (European Medicines Agency)
  • FDA (US Food and Drug Administration)
  • GlaxoSmithKline (GSK)
  • Merck & Co.
  • MHLW (Ministry of Health, Labour, and Welfare)
  • MHRA (Medicines and Healthcare Products Regulatory Agency)
  • NICE (the National Institute for Health and Care Excellence)
  • Novartis
  • Santen
  • Pfizer
  • Prima Biomed
  • Regeneron
  • Roche
  • WHO (World Health Organization)

The List Continues...

Back to Top